{"id":"levomepromazine","rwe":[],"tags":[{"label":"levomepromazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"N05AA02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Immunex","category":"company"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":321.327,"date":"","count":211,"signal":"Intentional overdose","source":"DrugCentral FAERS","actionTaken":"Reported 211 times (LLR=321)"},{"llr":286.77,"date":"","count":123,"signal":"Neuroleptic malignant syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 123 times (LLR=287)"},{"llr":279.525,"date":"","count":131,"signal":"Intentional self-injury","source":"DrugCentral FAERS","actionTaken":"Reported 131 times (LLR=280)"},{"llr":252.724,"date":"","count":208,"signal":"Drug abuse","source":"DrugCentral FAERS","actionTaken":"Reported 208 times (LLR=253)"},{"llr":249.802,"date":"","count":330,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 330 times (LLR=250)"},{"llr":228.94,"date":"","count":317,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 317 times (LLR=229)"},{"llr":220.307,"date":"","count":99,"signal":"Extrapyramidal disorder","source":"DrugCentral FAERS","actionTaken":"Reported 99 times (LLR=220)"},{"llr":195.079,"date":"","count":234,"signal":"Somnolence","source":"DrugCentral FAERS","actionTaken":"Reported 234 times (LLR=195)"},{"llr":169.462,"date":"","count":133,"signal":"Suicide attempt","source":"DrugCentral FAERS","actionTaken":"Reported 133 times (LLR=169)"},{"llr":162.491,"date":"","count":131,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 131 times (LLR=162)"},{"llr":161.051,"date":"","count":86,"signal":"Sopor","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=161)"},{"llr":150.323,"date":"","count":96,"signal":"Altered state of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=150)"},{"llr":98.574,"date":"","count":28,"signal":"Excessive eye blinking","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=99)"},{"llr":88.477,"date":"","count":49,"signal":"Psychomotor hyperactivity","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=88)"},{"llr":84.101,"date":"","count":16,"signal":"Dystonic tremor","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=84)"}],"drugInteractions":[{"url":"/drug/cyp2d6-substrates","drug":"CYP2D6 Substrates","action":"Use caution","effect":"Strong CYP2D6 Inducers - CYP2D6 Substrates","source":"DrugCentral","drugSlug":"cyp2d6-substrates"}],"commonSideEffects":[{"effect":"Neuroleptic malignant syndrome","drugRate":"LLR 287","severity":"common"},{"effect":"Intentional self-injury","drugRate":"LLR 280","severity":"common"},{"effect":"Drug abuse","drugRate":"LLR 253","severity":"common"},{"effect":"Drug interaction","drugRate":"LLR 250","severity":"common"},{"effect":"Toxicity to various agents","drugRate":"LLR 229","severity":"common"},{"effect":"Extrapyramidal disorder","drugRate":"LLR 220","severity":"common"},{"effect":"Somnolence","drugRate":"LLR 195","severity":"common"},{"effect":"Suicide attempt","drugRate":"LLR 169","severity":"common"},{"effect":"Electrocardiogram QT prolonged","drugRate":"LLR 162","severity":"common"},{"effect":"Sopor","drugRate":"LLR 161","severity":"common"},{"effect":"Altered state of consciousness","drugRate":"LLR 150","severity":"common"},{"effect":"Excessive eye blinking","drugRate":"LLR 99","severity":"common"},{"effect":"Psychomotor hyperactivity","drugRate":"LLR 88","severity":"common"},{"effect":"Dystonic tremor","drugRate":"LLR 84","severity":"common"}],"contraindications":["Acute disease of cardiovascular system","Alcoholism","Anemia","Angina pectoris","At risk for aspiration","Benign prostatic hyperplasia","Bradycardia","Breastfeeding (mother)","Carcinoma of female breast","Chronic disease of respiratory system","Chronic heart failure","Coma","Conduction disorder of the heart","Congenital long QT syndrome","Disease of liver","Epilepsy","Extrapyramidal disease","Glaucoma","Hyperglycemia","Hyperprolactinemia","Leukopenia","Metabolic syndrome X","Myocardial infarction","Myocardial ischemia","Neuroleptic malignant syndrome","Neutropenic disorder","Obesity","Organophosphate poisoning","Orthostatic hypotension","Parkinsonism","Prolonged QT interval","Retention of urine","Senile dementia","Stupor","Tardive dyskinesia","Thrombocytopenic disorder","Torsades de pointes","Visual impairment","Weight gain finding"]},"trials":[],"aliases":[],"company":"Immunex","patents":[],"pricing":[],"allNames":"nozinan","offLabel":[],"synonyms":["methotrimeprazine","hirnamin","levomeprazine","levomepromazin","levopromazine","levoprome","levopromethazine","levotomin","mepromazine","levomepromazine","levomepromazine maleate","methotrimeprazine hydrochloride","nozinan"],"timeline":[],"aiSummary":"Nozinan (Levomepromazine) is a small molecule drug that targets the histamine H1 receptor. It is classified as a levomepromazine and is off-patent, meaning it is no longer protected by patents. The exact approved indications for Nozinan are unknown, but it is likely used to treat conditions such as anxiety, insomnia, and nausea. Nozinan has a half-life of 30 hours and bioavailability of 50%. It is currently owned by Immunex, the company that originally developed it.","approvals":[{"date":"","orphan":false,"company":"IMMUNEX","regulator":"FDA"}],"brandName":"Nozinan","ecosystem":[],"mechanism":{"target":"Histamine H1 receptor, Pleiotropic ABC efflux transporter of multiple drugs","novelty":"First-in-class","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"}],"modality":"Small Molecule","drugClass":"levomepromazine","explanation":"Imagine your brain is like a busy city with many signals being sent and received. Histamine is like a messenger that helps to wake you up and make you feel alert. Nozinan blocks this messenger, helping to calm your brain and reduce symptoms of anxiety and insomnia.","oneSentence":"Nozinan works by blocking the action of histamine at the H1 receptor, which helps to reduce anxiety, insomnia, and other symptoms.","technicalDetail":"Levomepromazine acts as a competitive antagonist at the histamine H1 receptor, inhibiting the binding of histamine and reducing its effects on the central nervous system."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Levomepromazine","title":"Levomepromazine","extract":"Levomepromazine, also known as methotrimeprazine, is a phenothiazine neuroleptic drug. Brand names include Nozinan, Levoprome, Detenler, Hirnamin, Levotomin and Neurocil. It is a low-potency antipsychotic with strong analgesic, hypnotic and antiemetic properties that are primarily used in palliative care.","wiki_history":"== History ==\nThe drug (under the name Nozinan) started clinical trials in France in 1956 and was studied in Canada 3 years later."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1752","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LEVOMEPROMAZINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LEVOMEPROMAZINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Levomepromazine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:06:33.530799","biosimilars":[],"competitors":[{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"promazine","drugSlug":"promazine","fdaApproval":"1956-04-13","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acepromazine","drugSlug":"acepromazine","fdaApproval":"","relationship":"same-class"},{"drugName":"triflupromazine","drugSlug":"triflupromazine","fdaApproval":"1957-09-16","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"levomepromazine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-class"},{"drugId":"promazine","brandName":"promazine","genericName":"promazine","approvalYear":"1956","relationship":"same-class"},{"drugId":"acepromazine","brandName":"acepromazine","genericName":"acepromazine","approvalYear":"","relationship":"same-class"},{"drugId":"triflupromazine","brandName":"triflupromazine","genericName":"triflupromazine","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":["Schizophrenia Relapse"],"enrollment":139,"completionDate":"2017-01"},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":["Schizophrenia"],"enrollment":174,"completionDate":"2020-08"},{"nctId":"NCT02009306","phase":"PHASE4","title":"Nasal Fentanyl and Buccal Midazolam for Dying Patients","status":"COMPLETED","sponsor":"Gloucestershire Hospitals NHS Foundation Trust","startDate":"2017-01-23","conditions":["Terminal Cancer"],"enrollment":20,"completionDate":"2018-02-28"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"],"enrollment":725489,"completionDate":"2012-12"},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":["Psychosis Nos/Other"],"enrollment":104,"completionDate":"2015-11"},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":["Schizophrenia"],"enrollment":100,"completionDate":"2012-12"},{"nctId":"NCT00833300","phase":"NA","title":"Haloperidol vs Olanzapine for the Management of ICU Delirium","status":"TERMINATED","sponsor":"Richard Hall","startDate":"2008-06","conditions":["Delirium","Agitation"],"enrollment":200,"completionDate":"2011-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147208","MMSL":"1834","NDDF":"001581","UNII":"9G0LAW7ATQ","VUID":"4018915","CHEBI":"CHEBI:6838","VANDF":"4018915","INN_ID":"705","RXNORM":"160372","UMLSCUI":"C0025678","ChEMBL_ID":"CHEMBL1764","KEGG_DRUG":"D00403","DRUGBANK_ID":"DB01403","PUBCHEM_CID":"72287","SNOMEDCT_US":"387509007","IUPHAR_LIGAND_ID":"7603","SECONDARY_CAS_RN":"7104-38-3","MESH_DESCRIPTOR_UI":"D008728","MESH_SUPPLEMENTAL_RECORD_UI":"C017901"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Immunex","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"30.0 hours","clearance":"9.9 mL/min/kg","bioavailability":"50%","volumeOfDistribution":"12.0 L/kg"},"publicationCount":557,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AA02","allCodes":["N05AA02"]},"biosimilarFilings":[],"originalDeveloper":"Immunex","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Immunex","companyId":"immunex","modality":"Small molecule","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"IMMUNEX","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}